Themis Medicare Ltd

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. - However, the management discussed significant CapEx plans of around Rs. 40-45 crores annually for FY23, FY24, and FY25, implying potential funding needs. - Themis Lifestyle Private Limited (TSPL) is obligated to pay Themis Medicare Limited Rs. 125 crores as part of a demerger process, which may involve cash and/or share certificates. Themis Medicare, as the holding company, will support TSPL in this activity. - No direct statements regarding new debt or equity fundraising rounds were made during the call. - The company is also preparing for inorganic growth and significant investments, especially in the API business, which may imply future capital requirements, but no clear plans have been announced.

- Themis Medicare plans CapEx of around Rs. 40-45 crores per year for FY23, FY24, and FY25. - Significant CapEx is required for scaling up the API business to achieve next-level growth. - The company is preparing for inorganic growth in API by creating a subsidiary to allow focused expansion. - No plans to develop an online portal for hospital orders; existing distribution systems by specialized companies are preferred. - Partnership and inorganic opportunities, especially in the hospital business, are being explored to drive growth. - R&D investments continue with a focus on new drug delivery systems, APIs, and generic injectables, targeting new product launches every quarter to support revenue growth.

- Themis Medicare targets a 35% CAGR in consolidated revenue over the next 3 years, aiming to reach around Rs. 1,000 crores. - Current year revenue is expected to be close to last year’s level (~Rs. 400 crores), without COVID-related spikes. - Growth drivers include: - Significant increase in hospital business through expanded and more productive sales teams. - Increasing revenues from API business backed by new product launches and capacity expansions. - Strategic partnerships and inorganic growth opportunities, especially in hospital and API segments. - New products, particularly in APIs, are planned to launch quarterly, starting to contribute to topline within 6 months of exhibit batches. - Emphasis on organic growth supported by selective inorganic expansions to sustain targeted high growth.

- Themis Medicare aims for a consolidated revenue CAGR of 35% over the next 3 years, targeting around Rs. 1,000 crores top line. - Q3 FY23 revenues declined YoY due to COVID-related revenue drop, but PAT grew by 6.86% YoY. - EBITDA margin target is to improve from current ~20% to about 25% driven mainly by operating leverage and improved productivity without significant headcount increases. - New finished dosage form products are expected to have gross margins of 40-70%, contributing to margin expansion. - New API launches target gross contribution of about 50%, adding to EBITDA growth. - R&D efforts are expected to begin generating revenues roughly 6 months after exhibit batches, starting next quarter. - ROCE guidance for FY23 is around 25% to 30%, reflecting improved capital efficiency. - The growth strategy includes hospital business expansion, API business scaling, partnerships, and inorganic opportunities.

The transcript does not explicitly mention Themis Medicare Limited's current or expected order book or pending orders details. However, relevant points related to business outlook and related operational factors include: - Hospital business expected to be in line with last year, excluding Rs. 65 crore COVID-related one-time orders. - New intensive care division to be fully operational by March 2023, boosting hospital business. - API segment faced challenges due to increased input costs, leading to strategic reduction in production of a key API to meet contractual commitments. - Alternative manufacturing route for key API planned by end of Q4 FY23 or early next financial year. - Three additional APIs expected to go into commercial production by Q2 or Q3 FY24. - Strong R&D pipeline with plans to take 2 exhibit batches per quarter to increase product launches and revenues. No specific figures on order book or pending orders were disclosed in the call transcripts.